Updated REVLIMID(R) Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO
BOUDRY, Switzerland--(Business Wire)--
Celgene International Sarl (Nasdaq:CELG) today announced
preliminary data were presented from an international study of single
agent REVLIMID in relapsed/refractory non-Hodgkin's lymphoma (NHL-003,
Abstract #8509). The data was presented at the 44th Annual American
Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
In this study of heavily pretreated patients, 83 were eligible for
response evaluation. An objective response was observed in 29 percent
of patients, with six percent achieving a complete response (CR/CRu),
23 percent achieving a partial response and 19 percent showing stable
disease.
According to NHL histology, objective response was 36 percent in
mantle cell lymphoma, 22 percent in diffuse large b-cell lymphoma, 33
percent in follicular lymphoma (grade three) and 50 percent in
transformed lymphoma. These responses included several patients that
had been refractory to their prior therapies, including rituxamab
based regimens.
In the study, the most common grade 3 or higher adverse events
were neutropenia (27%), thrombocytopenia (15%), leucopenia (5%),
anemia (8%) and fatigue (5%).
"These data demonstrate that lenalidomide has activity in
relapsed/refractory aggressive NHL with a favorable safety profile,"
said Myron Czuczman, MD, Head, Lymphoma/Myeloma Section, Department of
Medicine at Roswell Park Cancer Institute and lead author of the
study. "Early results from this large, international study appear to
confirm the results obtained from an earlier, U.S. based, smaller
phase II study."
About REVLIMID(R)
REVLIMID is an IMiDs(R) compound, a member of a proprietary group
of novel immunomodulatory agents. REVLIMID and other IMiDs compounds
continue to be evaluated in over 100 clinical trials in a broad range
of oncological conditions, both in blood cancers and solid tumors. The
IMiDs pipeline is covered by a comprehensive intellectual property
estate of U.S. and foreign issued and pending patent applications
including composition-of- matter and use patents.
About Non-Hodgkin's Lymphoma
Lymphoma is the name for the group of blood cancers that start in
the lymphatic system, which is part of the body's immune system.
Lymphomas generally start in the lymph nodes or lymphatic tissue in
sites of the body such as the stomach or intestines. They may involve
the marrow and the blood in some cases as well. Most people with
lymphoma have one of the many different kinds of non-Hodgkin's
lymphoma (NHL).
About Celgene International Sarl
Celgene International Sarl, located in Boudry, Switzerland, is a
wholly owned subsidiary and international headquarters of Celgene
Corporation. Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global pharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through gene and protein regulation. For more information, please
visit the Company's website at www.celgene.com.
This release contains certain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other
factors not under the Company's control, which may cause actual
results, performance or achievements of the Company to be materially
different from the results, performance or other expectations implied
by these forward-looking statements. These factors include results of
current or pending research and development activities, actions by the
FDA and other regulatory authorities, and those factors detailed in
the Company's filings with the Securities and Exchange Commission such
as Form 10-K, 10-Q and 8-K reports.
Celgene Corporation
David Gryska, 908-673-9059
Sr. Vice President and Chief Financial Officer
or
Celgene Corporation
Brian P. Gill, 908-673-9530
Vice President, Corporate Communications
Copyright Business Wire 2008
